OUR PLATFORMS
Rooted in decades of experience in molecular biology, deep understandings of molecular diagnostics, and a wide range of OMICs technologies, Complete Omics has been working with world’s leaders in cancer proteomics and cancer genomics. Throughout the past decade, Complete Omics has established several robust platforms meeting the most demanding yet critical needs from basic research and clinical applications. We are well equipped to help you with your projects through our following patented or proprietary platforms:
Genomics
Patented DEEPER-Seq Platform — the world’s only barcoded single-strand library PLUS dual-RNA probe capture approach
Proteomics
Patented MT-SRM, SAFE-SRM, MANA-SRM, Neo-True Platforms — world’s leading authority in quantitative proteomics
Metabolomics
Proprietary MetaBoost chemical derivatizations for extremely sensitive detection and quantification of small molecules.
Please click on each specific technology above to learn more about Complete Omics’ expertise and our vision in clinical applications…
PIONEERING IN MULTI-OMICS CANCER DIAGNOSTICS SINCE 2010
In 2010, Dr. Qing Wang reported the 1st pipeline for detecting mutant proteins as cancer-specific biomarkers through Mass Spectrometry following NGS (next-generation sequencing)-based identification of personalized mutations (PNAS). Throughout the past 10 years, we have been pioneering the developments of clinical multi-omics technologies including the 1st clinical proteomics-based ovarian cancer diagnostic platform (PNAS), the 1st personalized cancer neoantigen therapeutic target detection and quantification platform (Science; Science Immunology; Science Advances), the most in-depth plasma proteomics pipeline (quantifying 4,550 proteins in plasma), the world’s only dual-RNA probe-based targeted NGS pipeline (DEEPER-Seq), etc. Backed by top publication records, we are looking for active clinical collaborators to test our clinical platforms. Any clinical project is welcome if it is addressing a pressing clinical need. BTW, Collaborations are Completely FREE! Just ask.
Detecting and Absolutely Quantifying Patient-specific Neoantigens from Limited Input of Biopsy Sample — An Integrated Pipeline for Neoantigen-targeted Cancer Treatments
Neoantigens derived from HERVs represent a new group of cancer therapeutic targets. In a collaborating project, Complete Omics identified and quantified HERVs derived neoantigens and provided solid evidence for developing targeted therapies.
Identifying and Quantifying Neoantigens derived from Human endogenous retroviruses (HERVs) — A new class of targets to expand the benefits of cancer immunotherapy.
Neoantigens derived from HERVs represent a new group of cancer therapeutic targets. In a collaborating project, Complete Omics identified and quantified HERVs derived neoantigens and provided solid evidence for developing targeted therapies.
Happy Holidays from Complete Omics!
December 23, 2021 | BALTIMORE – Dear Team Members and Friends: 2021 has been an exciting year for Complete Omics – – we brought dramatic improvements to biomedical sciences and patient care by advancing our multi-omics molecular diagnostic pipelines even further. In the year of 2021, over 80 new research papers featuring Complete Omics’ technologies and platforms have been published. Since 2021 summer, Complete Omics started to offer cutting-edge multi-omics research services backed up by our top profile publications and patents. Now we are thrilled to work with over 30 pharmaceutical corporations and over 50 research labs worldwide to implement our Complete360® multi-omics molecular diagnostic pipeline and our Valid-NEOTM companion diagnostics pipeline. Hundreds of novel biomarkers and dozens of new drug targets are identified and quantified by us, and numerous treatment approaches are being developed based on our discoveries. We expect massive new features to be added on to our platforms over the next few years, and many exciting new discoveries ahead from ourselves and from the collaborations with scientists throughout the world. Please follow our company’s progress or contact us at info@completeomics.com to learn more about how we can advance your research and patient care. All of us at Complete Omics wish you a Merry Christmas and Happy New Year of 2022!
“We see each individual as an integrity of multiple universes. We are striving to provide the most sensitive and specific health surveillance tests through measuring the individual’s different pools of biological molecules simutaneously.”
— Qing Wang, Founder and CEO
Our People | check here for the team of Complete Omics |
Complete Omics is incorporated by a vibrant team of excellent scientists. With decades of expertises in molecular diagnostics and Omics-based technologies, our scientists and directors are building something fantastic for human population. We are hiking alone, but are determined to change the world!
2022–Direct Identification and Quantification of Neoantigens from Minute Amount of Clinical Biopsy Sample — published on Cancers
In recent years, neoantigens are becoming popular cancer therapeutic targets under intensive studies by almost all major oncology pharmaceuticals. However, who are the target patients? Does the patient with a “correct” mutation and a “correct” HLA allele indeed present the “correct” neoantigen? Is this individual’s neoantigen copy number high enough for immunotherapy? AI predictions based on NGS genomic information have been proven incapable of answering these questions. Immunopeptidome through mass spectrometry is dominated by disease-irrelevant peptide sequences. There is no existing way to identify and quantify neoantigens from a minute amount of clinical biopsy sample, such as 50 mg tissue or less. Valid-NEO is developed to fit this demanding clinical need through combining our proprietary multi-omics platforms including NGS-based ultra-rare mutation calling technique, DEEPER-SeqS, and our unique clinical proteomics platform, Complete360®, with additional hardware innovations (Ref. 1).
Valid-NEO: Multi-omics Pipeline for Neoantigen Assays
Latest News
Collaboration with Columbia University
Mar 30, 2022 | BALTIMORE – Complete Omics’ Clinical Proteomics team announced a collaboration with Professor Kam W. Leong, Samuel Y. Sheng professor of Biomedical Engineering, and his team from…
Collaboration with Tel Aviv University
Mar 20, 2022 | BALTIMORE – Complete Omics’ Clinical Proteomics team announced a collaboration with Professor Miguel Weil from Department of Cell Research and Immunology at the Tel Aviv University…
Detecting and Absolutely Quantifying Patient-specific Neoantigens from Limited Input of Biopsy Sample — An Integrated Pipeline for Neoantigen-targeted Cancer Treatments
Neoantigens derived from HERVs represent a new group of cancer therapeutic targets. In a collaborating project, Complete Omics identified and quantified HERVs derived neoantigens and provided solid evidence for developing…
